Safety, Efficacy and Pharmacokinetic Study of Teduglutide in Infants 4 to 12 Months of Age With Short Bowel Syndrome

Shire

Status and phase

Completed

Phase 3

Conditions

Short Bowel Syndrome

Treatments

Other: Standard Medical Therapy

Device: Needle

Drug: Teduglutide

Device: Syringe

Study type

Interventional

Funder types

Industry

Identifiers

NCT03571516

2017-003606-40 (EudraCT Number)

SHP633-301

Details and patient eligibility

About

The purpose of the study is to evaluate the safety, efficacy/pharmacodynamics (PD) and pharmacokinetics (PK) of teduglutide treatment in infants with short bowel syndrome (SBS) dependent on parenteral (PN) support.

Enrollment

10 patients

Sex

All

Ages

4 to 12 months old

Volunteers

No Healthy Volunteers

Inclusion criteria

Informed consent by the parent or legal guardian.
Male or female infant 4 to 12 months corrected gestational age at screening.
Weight at least 5 kilogram (kg) and weight-for-length Z-score greater than -2 at screening and baseline.
Short bowel syndrome with dependence on parenteral support to provide at least 50% of fluid or caloric needs.
Stable PN requirements for at least 1 month prior to screening, defined as a less than or equal to (<=) 10% change in the weight-normalized PN total fluid and caloric intake, despite attempts to wean PN, not withstanding transient instability for events such as sepsis or interruption of central venous access.
Parent or legal guardian understands and is willing and able to fully adhere to study requirements as defined in this protocol.

Exclusion criteria

Previous treatment with teduglutide.
Intestinal malabsorption due to a genetic condition, such as cystic fibrosis, microvillus inclusion disease, etc.
Severe, known dysmotility syndrome, such as pseudo-obstruction or persistent, severe, active gastroschisis-related dysmotility, that is the primary contributing factor to feeding intolerance and inability to reduce PN support, prior to screening. Dysmotility is defined as severe if it is expected to limit the advancement of enteral feeding.
Inability to advance oral or enteral feeding due to lack of access to the gut, such as oral aversion in the absence of a feeding tube.
Intestinal obstruction or clinically significant intestinal stenosis.
Major gastrointestinal surgical intervention, such as serial transverse enteroplasty or major intestinal resection or anastomosis, within 3 months prior to screening or planned during the study period.
Unstable cardiac disease.
Renal dysfunction, defined as estimated glomerular filtration rate less than (<) 50 milliliter per minute (mL/min) per 1.73 square meter (m^2).
Biliary obstruction, stenosis, or malformation.
Clinically significant pancreatic disease.
Severe hepatic dysfunction or portal hypertension, defined by at least 2 of the following parameters:
1. International normalized ratio (INR) greater than (>) 1.5 not corrected with PN vitamin K
2. Platelet count <100×10^3/ microliter (mcL) due to portal hypertension
3. Presence of clinically significant gastric or esophageal varices
4. Documented cirrhosis
Persistent cholestasis defined as conjugated bilirubin >4 milligram per deciliter (mg/dL) (>68 micromoles per liter [mcmol/L]) over a 2 week period.
More than 3 serious complications of intestinal failure (example [e.g.], catheter-associated bloodstream infections, interruption of nutrition due to feeding intolerance, catheter-associated thrombosis, severe fluid or electrolyte disturbances) within 1 month prior to or during screening.
A history of cancer or a known cancer predisposition syndrome, such as juvenile polyposis or Beckwith-Wiedemann syndrome, or first degree relative with early onset of gastrointestinal cancer (including hepatobiliary and pancreatic cancers).
Concurrent treatment with glucagon-like peptide-1 (GLP-1); glucagon-like peptide-2 (GLP-2); insulin-like growth factor-1 (IGF-1); growth hormone, somatostatin, or analogs of these hormones; or glutamine.
Participation in a clinical study using an experimental drug within 3 months or 5.5 half-lives of the experimental drug, whichever is longer.
Known or suspected intolerance or hypersensitivity to the investigational product, closely-related compounds, or any of the stated ingredients.
Any condition, disease, illness, or circumstance that, in the investigator's opinion, puts the participant at any undue risk, prevents completion of the study, or interferes with analysis of the study results.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

10 participants in 2 patient groups

Teduglutide

Experimental group

Description:

Participants will receive 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection of teduglutide into abdomen or into either the thigh or arm once daily (QD) in addition to standard medical therapy for 24 weeks.

Treatment:

Other: Standard Medical Therapy

Device: Needle

Drug: Teduglutide

Device: Syringe

Standard of Care (SOC)

Other group

Description:

Participants will receive standard medical therapy for 24 weeks.

Treatment:

Other: Standard Medical Therapy

Device: Needle